Multiple endocrine neoplasia type 2 screening: Difference between revisions
Line 24: | Line 24: | ||
|- | |- | ||
| rowspan="1" style="font-size: 95%; padding: 0 5px; background: #F5F5F5" | ▸ Individuals with c-[[RET gene|RET]] codon 609, 611, 618, 620, 630, 634, 790, V804L, 883, 918 or 922 mutations should be routinely screened for [[pheochromocytoma]] by annual determinations of fractionated [[Urinary system|urinary]] and free plasma [[metanephrine]]s and [[catecholamine]]s. | | rowspan="1" style="font-size: 95%; padding: 0 5px; background: #F5F5F5" | ▸ Individuals with c-[[RET gene|RET]] codon 609, 611, 618, 620, 630, 634, 790, V804L, 883, 918 or 922 mutations should be routinely screened for [[pheochromocytoma]] by annual determinations of fractionated [[Urinary system|urinary]] and free plasma [[metanephrine]]s and [[catecholamine]]s. | ||
|} | |} | ||
* [[Screening]] of the [[pregnant]] woman with an increased risk of multiple endocrine neoplasia type 2 is recommended to identify mutations in the [[RET gene|''RET'' gene]] of the offspring. | * [[Screening]] of the [[pregnant]] woman with an increased risk of multiple endocrine neoplasia type 2 is recommended to identify mutations in the [[RET gene|''RET'' gene]] of the offspring. |
Revision as of 13:48, 24 June 2019
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 screening On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 screening |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
According to the American Society of Clinical Oncology, screening for multiple endocrine neoplasia type 2 by RET gene testing is recommended for children with increased risk of multiple endocrine neoplasia type 2.
Screening
- The DNA-based testing of the c-RET gene is recommended for children with increased risk of multiple endocrine neoplasia type 2.
- The DNA-based testing of the c-RET gene can be easily performed on a blood sample at any age.
- The DNA-based testing of the c-RET gene offers the opportunity for early identification of the c-RET germline mutations, thus contributing to the reduction of morbidity and mortality of multiple endocrine neoplasia type 2 syndrome. In fact, the early recognition of the mutant gene carriers makes possible the prevention and cure of medullary thyroid cancer, by performing a prophylactic thyroidectomy before the clinical expression of the tumor.
- The DNA-based testing of the c-RET gene test is also of importance to detect and thus, to reduce the risk of an unsuspected pheochromocytoma.[1]
- Screening for multiple endocrine neoplasia type 2 include the following tests.[2]
References
|